Focus Area: Immunotherapy
Immunotherapy is defined as the treatment of disease through induction, enhancement, or suppression of an immune response. The human immune system is remarkable in its ability to recognize and destroy pathogens while leaving healthy cells intact, minimizing side effects. These properties have driven an overwhelming interest in the manipulation of the immune system to effectively fight disease. Since the 1800s, vaccines have been used to train and stimulate the immune system to fight against diseases like the flu and chickenpox. Recent studies have suggested that a similar approach can be taken to combat more complex diseases, albeit through a different mechanism. Our company’s research focuses on the successful application of immunotherapeutics to combating diseases such as cancer and AIDS
Focus Area: Oncology
The field of immunotherapeutics holds much promise for the treatment of cancer. Our immunotherapy research efforts have resulted in the novel cancer drug MA-8789, an anionic alkali mineral solution composed of (minerals). MA-8789 has yielded positive anti-tumor efficacy results in both in vitro and in vivo, and has exhibited immunostimulatory effects through increasing lymphocyte and cytokine counts. Animals treated with MA-8789 have exhibited increased CD4+, CD8+, CD4+CD25+, CD8+CD25+, and B-lymphocytes in horses [1], and CD4+CD8+ T lymphocytes in pigs [2]. Murine studies have shown increases in CD4+, CD8+, CD4+CD25+, CD8+CD25+ T-lymphocytes, as well as CD28+ NK cells with intracellular IFN-γ and TNF-α expression[3]. Anecdotal evidence has supported our hypothesis that MA-8789 can effectively induce complete tumor regression in humans with minimal side effects.
Our current research is focused on two areas: finalizing MA-8789’s use as a human cancer treatment and defining the mechanism that makes MA-8789 such a revolutionary drug. Our researchers are currently proposing efficacy and pharmacology tests to ensure MA-8789’s safety and effectiveness.
Our current research is focused on two areas: finalizing MA-8789’s use as a human cancer treatment and defining the mechanism that makes MA-8789 such a revolutionary drug. Our researchers are currently proposing efficacy and pharmacology tests to ensure MA-8789’s safety and effectiveness.
Focus Area: Virology
Retroviruses such as human immunodeficiency virus (HIV) have been shown to cause autoimmune deficiency syndrome (AIDS). AIDS is marked by a gradual failure of the immune system due to HIV infection of CD4+ cells, dendritic cells, and macrophages, giving rise to opportunistic infections and tumors. In vivo studies on MA-8789 exhibit increases in CD4+ cells among others [1, 2, 3], suggesting that MA-8789 could counter the effects of AIDS. The global AIDS pandemic has prompted us to expand our immunotherapy research to include the potential application of MA-8789 to treat AIDS. Our researchers are in the process of proposing studies to illustrate the possible relationship MA-8789 could have with AIDS remission.
